Clinical Trials Directory

Trials / Unknown

UnknownNCT06082388

Atropine vs Isoprenaline in the Invasive Diagnosis of Arrhythmias

Comparison of the Clinical Utility of Atropine and Isoprenaline in the Invasive Diagnosis of Arrhythmias

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Medical University of Lodz · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

During electrophysiological study (EPS) multiple drugs are used to reveal arrhythmias and/or conductive system disorders. Two most often used agents are atropine and isoprenaline. Due to their distinct pharmacological properties, they are affecting myocardium in different manner. Those dissimilarities can affect the EPS course and long-term prognosis. The aim of presented study is to evaluate the optimal protocol of pharmacotherapy during EPS.

Detailed description

Electrophysiological study (EPS) is essential tool for heart rhythm disorders diagnostic. Inducibility of arrhythmia before ablation to confirm the diagnosis and inability to do so after the procedure is crucial for long-term success. Multiple drugs are used to reveal arrhythmias and/or conductive system disorders. Two most often used are atropine and isoprenaline. Atropine is a natural, selective antagonist of cholinergic receptors M1 and M2. It reverses the inhibitory effect of vagal nerve on myocardium. This improves sinus node automatism and conduction in atrioventricular node. Isoprenaline is a preferential agonist of beta-1-adrenergic receptors. It has bathmotropic and chronotropic effect. During daily clinical practice those two drugs are often used interchangeably. However, differences in pharmacokinetics and pharmacodynamics may affect the results. There are lack of data directly comparing those two agents. There are isolated evidences that arrhythmia inducibility rate after the ablation differs between those two drugs. This may lead to the misconception of ablation as successful. The aim of presented study is to evaluate the optimal protocol of pharmacotherapy during EPS.

Conditions

Interventions

TypeNameDescription
DRUGComparison of atropine and isoprenalineComparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline

Timeline

Start date
2023-11-09
Primary completion
2025-09-01
Completion
2025-12-01
First posted
2023-10-13
Last updated
2023-10-13

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT06082388. Inclusion in this directory is not an endorsement.